Devonian Health GroupDVHGF 49 Beneish M-Score is -0.84 as of Jul. 03, 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $3.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 829 Biotechnology companies, Devonian Health Group ranks worse than 79.37% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score -0.84 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Devonian Health Group's Beneish M-Score or its related term are showing as below:
DVHGF'
s Beneish M-Score Range Over the Past 10 Years
Min: -11.73 Med: -2.06 Max: 74.05
Current: -0.84
During the past 12 years, the highest Beneish M-Score of Devonian Health Group was 74.05. The lowest was -11.73. And the median was -2.06.
Devonian Health Group Beneish M-Score Related Terms
Devonian Health Group Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVHGF vs VRTX, REGN, ALNY: Beneish M-Score Comparison
For the Biotechnology subindustry, Devonian Health Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Devonian Health Group for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.3254
+
0.528 * 0.7796
+
0.404 * 1.5043
+
0.892 * 0.3328
+
0.115 * 2.2114
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 2.6192
+
4.679 * 0.582554
-
0.327 * 0.3327
=
-0.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(0.463 / (0.463 + 1.639))
/
(0.176 / (0.176 + 1.591))
=
0.220266
/
0.099604
=
2.2114
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-6.45 - -3.461
-
-7.036)
/
6.947
=
0.582554
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Devonian Health Group has a M-score of -0.80 signals that the company is likely to be a manipulator.
Devonian Health Group (DVHGF) has a Beneish M-Score of -0.84 as of Jul. 03, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Devonian Health Group and its competitors. According to the industry distribution chart, Devonian Health Group ranks #658 out of 829 companies in the Biotechnology industry, placing it in the top 79.4%.
Is Devonian Health Group's Beneish M-Score too high?
Devonian Health Group's current Beneish M-Score is -0.84. Based on the distribution chart, Devonian Health Group ranks #658 out of 829 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Devonian Health Group ranks #658 out of 829 companies for Beneish M-Score. This places Devonian Health Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Beneish M-Score is -0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current Beneish M-Score is -0.84. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Beneish M-Score is -0.84 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Beneish M-Score: -0.84
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
